Inlyta, also known by its generic name axitinib, is a medication commonly used in the treatment of advanced renal cell carcinoma (kidney cancer). It belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking the action of certain proteins that promote the growth of cancer cells.

Patients prescribed Inlyta should be aware of the potential side effects associated with this medication. Common side effects may include diarrhea, high blood pressure, fatigue, nausea, and decreased appetite. It is important to communicate any side effects experienced while taking Inlyta to your healthcare provider, as they may be able to provide guidance on managing these symptoms.

As with any medication, it is crucial to follow the dosing instructions provided by your healthcare provider and to not adjust your dosage without consulting them first. Inlyta is typically taken orally, with or without food, as directed by your doctor.

It is important to inform your healthcare provider of any other medications, supplements, or herbal products you are taking, as they may interact with Inlyta and affect its effectiveness or increase the risk of side effects.

Regular monitoring and follow-up appointments with your healthcare provider are essential while taking Inlyta to assess your response to the medication and monitor for any potential complications.

Overall, Inlyta can be an effective treatment option for patients with advanced renal cell carcinoma, but it is important to be informed about the medication, its potential side effects, and to communicate openly with your healthcare provider throughout your treatment journey.